OĞUZ ÖZTÜRK, OGUZHAN ZENGİN, MUZAFFER SERDAR DENİZ, ENES SEYDA ŞAHİNER, OSMAN İNAN, OZCAN EREL, İHSAN ATEŞ
Ankara City Hospital Medical Journal - 2023;2(3):90-96
INTRODUCTION: In this study, it was aimed to evaluate the relationship between the use of two different sodium glucose transporter 2 (SGLT-2) inhibitors, dapagliflozin and empagliflozin, and renal tubular injury, with type 2 diabetes mellitus patients obtaining levels of neutrophil gelatinase-associated lipocalin (NGAL) in serum and arylesterase in urine. METHODS: Sixty patients diagnosed type 2 diabetes mellitus were enrolled in the study; 30 of these patients used dapagliflozin and 30 patients used empagliflozin. The serum NGAL levels of the patients were measured by sandwich ELISA method while urine arylesterase levels were studied by centrifugation. Results: No significant relationship was found between the considered SGLT-2 inhibitors and the occurrence of acute tubular damage. There was no significant difference in serum NGAL levels or urinary arylesterase levels between the dapagliflozin and empagliflozin groups. The levels of microalbuminuria were significantly decreased in both groups. DISCUSSION AND CONCLUSION: It can be said that there is no significant relationship between SGLT-2 inhibitors and renal tubular damage, with no significant difference found between dapagliflozin and empagliflozin.
